Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
[eBook] Therapeutic proteins: bioprocessing methods for mAb generation
How to optimise your bioprocess for monoclonal...
How to ensure lab compliance and maximise your productivity
[Infographic] Transform your lab in the cloud |...
How to streamline your research from molecule to medicine — case studies
Learn how organisations are leveraging the latest...
